A Dose-Finding Study of MM-120 for the Treatment of Anxiety Symptoms

• Status: Recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mind Medicine, Inc.

Criteria

Inclusion Criteria:

• Bodyweight of ≥ 50 kg

• Body mass index [BMI] ≥ 18 to ≤ 38 mg/kg2

• Diagnosis of DSM-5 generalized anxiety disorder

• Acceptable overall medical condition to be safely enrolled into and to complete the study

• Ability to swallow capsules

• Ability to provide informed consent

Exclusion Criteria:

• Women of childbearing potential (WOCBP) (i.e., physiologically capable of becoming pregnant) who are unwilling or unable to use a highly effective method of contraception for the duration of the study, OR Men physiologically capable of fathering a child who are sexually active with WOCBP but are unwilling or unable to use barrier contraception (e.g., condom with or without spermicidal cream or jelly) for the duration of the study

• Women who are currently pregnant or breastfeeding or plan to become pregnant or breastfeed during the study

• Men who plan to donate sperm during the study

• Prior history (lifetime diagnosis) or known first-degree relative (i.e., mother/father/full siblings) with a lifetime diagnosis of schizophrenia spectrum, posttraumatic stress disorder or other psychotic disorders or bipolar disorder

• Has a significant risk of suicide attempt based upon medical history or has active suicidal ideation

• Unwillingness or inability to discontinue prohibited concomitant medications, supplements or other therapeutics (prescription or over-the-counter)